Key terms

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest NTLA news

Yesterday 11:18am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Apr 15 4:32pm ET Intellia Therapeutics Welcomes New Principal Accounting Officer by TipRanks Apr 08 9:50pm ET Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA) by TipRanks Mar 22 9:42am ET Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals by TipRanks Mar 18 7:38am ET Intellia Therapeutics announces first patient dosed in Phase 3 MAGNITUDE study by TipRanks Mar 04 12:20am ET 5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024 by TipRanks Feb 27 7:48am ET Intellia Therapeutics (NTLA) Gets a Buy from Truist Financial by TipRanks Feb 26 8:10am ET Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE) by TipRanks Feb 26 7:10am ET Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA) by TipRanks Feb 25 11:36pm ET Hold Rating for Intellia Therapeutics Amid Clinical Trials and Competitive Dynamics by TipRanks Feb 25 11:30pm ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Feb 25 11:30pm ET Buy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial Health by TipRanks Feb 24 10:16am ET Intellia Expands At-The-Market Offering Program with Jefferies by TipRanks Feb 23 9:25am ET Intellia Therapeutics: A Measured Hold Amid Competitive and Timeline Challenges by TipRanks Feb 23 9:18am ET Intellia Therapeutics downgraded to Neutral from Buy at Goldman Sachs by TipRanks Feb 23 8:47am ET Intellia Therapeutics price target lowered to $64 from $78 at Guggenheim by TipRanks Feb 23 7:38am ET Strong Buy Rating for Intellia Therapeutics Amid Positive Trial Updates and Robust Financial Standing by TipRanks Feb 23 7:38am ET Intellia Therapeutics: A Buy Rating with Increased Price Target Amidst Strong Pipeline Progress and Financial Stability by TipRanks Feb 23 7:22am ET Intellia Therapeutics price target raised to $73 from $72 at Canaccord by TipRanks Feb 23 7:19am ET RBC Capital Sticks to Their Buy Rating for Intellia Therapeutics (NTLA) by TipRanks Feb 23 3:20am ET Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tandem Diabetes Care (TNDM) by TipRanks Feb 23 12:16am ET Intellia Therapeutics: Hold Rating Maintained Amid Fair Valuation and Anticipated Clinical Milestones by TipRanks Feb 22 2:50pm ET Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI) by TipRanks Feb 22 7:35am ET Intellia Therapeutics reports Q4 EPS ($1.46), consensus ($1.45) by TipRanks Feb 16 7:32am ET Buy Rating for Intellia Therapeutics: Strategic CF Therapy Partnership Enhances Pipeline and Promises Growth by TipRanks Feb 16 7:14am ET Intellia Therapeutics price target lowered to $24 from $38 at Baird by TipRanks Feb 15 7:43am ET Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF by TipRanks Feb 15 7:36am ET Intellia Therapeutics, ReCode Therapeutics announce collaboration by TipRanks Feb 14 7:23pm ET Intellia Therapeutics initiated with a Peer Perform at Wolfe Research by TipRanks Feb 14 4:16pm ET Intellia Therapeutics initiated with a Peer Perform at Wolfe Research by TipRanks Feb 05 8:04pm ET Cathie Wood’s ARK Investment bought 131K shares of Intellia Therapeutics today by TipRanks
Mar 15 12:40pm ET Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm by Newsfile

NTLA Financials

1-year income & revenue

Key terms

NTLA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

NTLA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally
A working oil pumpjack is pictured in Taft, Kern County, California on September 21, 2023.
Frederic J. Brown/AFP/Getty Images
Oil prices get short-lived boost from attack on Iran
NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days